Barcelona HealthTech Startup Secures €2.1 Million to Revolutionize Hospital Efficiency with AI and Data Analytics

Health Lean Analytics (HLA), a startup based in Barcelona, has successfully completed a funding round, raising over €2.1 million in total. The funding includes a combination of private and public funds, with Novanta, a US-listed company, becoming a strategic partner. Novanta will provide technological expertise and access to the US market, supporting HLA in its growth phase.

Various family offices, such as Inderhabs, Namarel, and Braincats, also participated in the oversubscribed Seed funding round of €1.4 million. Additionally, HLA secured a loan from the Spanish National Innovation Company (ENISA). This follows the successful closure of a Seed round last year, which raised more than €750k.

Co-founder and Co-CEO of HLA, Mauro Batesteza, expressed excitement about the partnership with Novanta, highlighting the opportunities it brings for R&D innovation. The collaboration aims to accelerate commercial deployment in the US market and showcase how HLA’s technology can improve hospital management, enhancing efficiency, safety, and patient care quality.

Established in 2023, Health Lean Analytics focuses on using data and artificial intelligence to improve hospital operations. The company’s solutions leverage data automation, IoT, advanced analytics, and AI, with a specific emphasis on the surgical suite within hospitals. HLA’s technology captures real-time clinical and operational data without manual input and integrates seamlessly with existing hospital systems.

The company’s AI-driven platform interprets hospital data to provide actionable insights, predicting deviations and recommending specific actions. This approach aims to reduce costs, optimize surgical capacity, enhance safety and care quality, and improve healthcare professionals’ experience.

Novanta’s Co-COO, John Lesica, praised HLA’s AI and data analytics platform for transforming hospital operations into actionable intelligence. He highlighted the synergy between Novanta’s technologies and HLA’s platform, emphasizing the potential to revolutionize hospital workflows, starting with the operating room.

With the new funding, HLA plans to strengthen its presence in the domestic market and expand internationally, starting with the United States. The company also aims to enhance its R&D capabilities, focusing on data automation, advanced analytics, and AI. The goal is to continue innovating and driving growth in the healthcare sector.